Alan S. Wayne, MD

Chair, Department of Pediatrics

Professor of Pediatrics, Medicine, and Cancer Biology, Keck School of Medicine of USC

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair Children's Hospital Los Angeles

Image of Alan S. Wayne, MD
Is this your profile? Click to edit

Overview

Alan S. Wayne, MD serves as Chair of the Department of Pediatrics at the Keck School of Medicine of USC and Senior Vice President of Academic Affairs and Pediatrician-in-Chief at Children’s Hospital Los Angeles (CHLA). Dr. Wayne is Professor of Pediatrics and Medicine at the Keck School of Medicine of USC. In these roles, Dr. Wayne oversees the Department’s clinical care delivery, medical education, and research programs, and leads the departmental strategy, faculty affairs, and budget management in the context of the missions of USC and CHLA.

Dr. Wayne’s primary research efforts are directed toward the development of new treatment approaches for leukemias and lymphomas, with a focus on targeted, immune-based, and cellular therapies. He is the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group headquartered at CHLA. He has an ongoing leadership role in the development of genetically modified chimeric antigen receptor (CAR) T-cells for childhood hematologic malignancies. Additionally, he plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies, the primary aim of which is to study the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation.

Board-certified in pediatric hematology-oncology, Dr. Wayne attended the Honors Program in Medical Education obtaining his BS and MD degrees from Northwestern University. He conducted internship, residency, and chief residency in pediatrics at Boston Children’s Hospital followed by pediatric hematology-oncology fellowship at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

Research Funding

  • Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
    NIH · U01AI126612 · Aug 24, 2017 – Jul 31, 2024 · Role: Principal Investigator
  • University of Southern California Norris Comprehensive Cancer Center Support Grant (CCSG)
    NIH · P30CA014089 · Apr 1, 1980 – Nov 30, 2026 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · Z01BC010596 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · Z01BC010764 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · Z01SC010353 · Role: Principal Investigator
  • Pediatric Graft-vs-Host Disease
    NIH · ZICBC010596 · Role: Principal Investigator
  • Behavioral Science Core
    NIH · ZICBC011288 · Role: Principal Investigator
  • Experimental Therapeutics of Pediatric Hematopoietic Malignancies
    NIH · ZICSC010353 · Role: Principal Investigator
  • Pediatric Oncology Branch Clinical Care and Education
    NIH · ZIEBC010764 · Role: Principal Investigator

Publications

  • NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.. View in PubMed
  • Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010 Nov; 95(11):1873-9.. View in PubMed
  • Long-term remission in a child with refractory EBV(+) hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV(+)-related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy. Bone Marrow Transplant. 2011 May; 46(5):759-61.. View in PubMed
  • NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.. View in PubMed
  • NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211.. View in PubMed
  • Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol. 2010 Aug; 150(3):352-8.. View in PubMed
  • Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15; 16(6):1894-903.. View in PubMed
  • Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4.. View in PubMed
  • The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010 Apr 15; 115(15):3017-24.. View in PubMed
  • Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther. 2010 Feb; 10(2):163-78.. View in PubMed